GHIT R&D Forum

December 6th, 2019

Tokyo Garden Terrace Kioi Conference

GHIT Fund

Global Health Innovative Technology Fund

GHIT R&D Forum

Program

8:00 - 9:00		Registration & Networking Breakfast
9:00 - 9:05		Greetings and Opening Remarks
9:10 - 9:50	Session 1	PDP perspectives on unmet medical needs in malaria, TB, and NTDs
9:55 - 11:05	Session 2	Discovery-stage technologies and innovations to address unmet medical needs
11:10 - 12:05	Session 3	Development-stage technologies and innovations to address unmet medical needs
12:05 - 13:30		Lunch Break (12:05 - 13:30) Lunch Session: Proposal Writing Seminar (12:15 - 13:00) Booth Exhibition (12:05 - 13:30)
13:30 - 13:55		Activity
14:00 - 14:55	Session 4	Partnership matters! Coincidence or destiny? How and where can we meet the right partners?
15:00 - 15:55	Session 5	Partnership matters!- Unlocking the secret of successful partnerships for late-stage projects
15:55 - 16:25		Coffee Break Booth Exhibition
16:25 - 17:20	Session 6	Funders' role and strategy in catalyzing innovations for neglected patients
17:25 - 17:30		Closing Remarks



Greetings and Opening Remarks

Dr. Hiroki Nakatani

GHIT Fund
Chair & Representative Director

Dr. Hiroki Nakatani served as Assistant Director-General of WHO from March 2007 to May 2015. He led the largest technical cluster comprising HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication in case of dracunculiasis (guinea worm disease). Before joining WHO, he worked at the Ministry of Health, Labour and Welfare of Japan. Dr. Nakatani received his M.D. from Keio University School of Medicine, M.H.P.Ed from the University of New South Wales, and Ph.D. from Keio University.

Ms. Catherine K. Ohura

GHIT Fund
CEO & Executive Director

Catherine Kaseri Ohura is CEO & Executive Director of the GHIT Fund — Previously, she served as the Executive Officer and Unit Head of Japan Commercial Operations & Customer Experience at Bristol-Myers Squibb (BMS) K.K. (located in Japan). She also served as Executive Officer and Senior Director, Regional R&D Operations (responsible for Japan, China R&D Operations) at BMS K.K. At BMS (in the US), one of her roles was the Global Lead/General Manager for the BMS Network of Women (B-NOW). In this groundbreaking industry leadership role, she drove business performance at BMS globally by fostering a more powerfully diverse and broadly inclusive people and business strategy. Prior to her role at BMS, Ohura worked in Japanese pharmaceutical company for clinical development, regulatory affairs, quality assurance, pharmacovigilance, and project management. She received her undergraduate degree in chemistry, mathematics, and business from the University of Denver, and a master's degree in regulatory affairs and quality assurance from Temple University School of Pharmacy. She has completed all but dissertation in the PhD program for Project Management at Capella University and is PMP (Project Management Professional) certified.

Session 1:

PDP perspectives on unmet medical needs in malaria, TB, and NTDs

Dr. Takushi Kaneko

Senior Research Fellow
TB Alliance

Dr. Takushi Kaneko is a Senior Research Fellow at TB Alliance, a not-for-profit organization dedicated to the discovery, development, and delivery of better, faster-acting, and affordable tuberculosis drugs. He joined TB Alliance in 2007 and has been responsible for overseeing drug discovery research activities between TB Alliance and collaborating pharmaceutical companies and academic institutions. Before joining TB Alliance, he was a Research Fellow in the Antibacterial Drug Discovery Group at Pfizer Global Research and Development Division in Groton, CT (1989-2007). He also managed the Natural Product Discovery Team in Pfizer in Groton. Prior to Pfizer, Dr. Kaneko worked in the Oncology Drug Discovery Group in Bristol-Myers Pharmaceutical Research and Development Division in Wallingford, CT (1977-1989). He earned his BSc degree from the University of Missouri at Columba (1970) and his MS and PhD in organic chemistry from the University of Michigan under Professor J. P. Marino (1974). He later carried out postdoctoral research at Harvard University with Professor Y. Kishi.

Dr. Charles Mowbray

Discovery Director
DND*i*

Dr. Charles Mowbray is the Discovery Director at DND*i* responsible for advancing new chemical entities into development. He joined DND*i* in 2011 and has worked extensively on leishmaniasis and other kinetoplastid diseases. Dr. Mowbray also conceived the NTD Drug Discovery Booster consortium with 8 global pharmaceutical companies. He serves as an expert advisor to organisations working on medicinal chemistry, neglected diseases and global health projects. Dr. Mowbray joined Pfizer in Sandwich, UK in 1992 and spent 19 years working as a medicinal chemist and project leader across multiple diseases, target classes and medicinal chemistry strategies and from target selection through to clinical candidate delivery. Five of these drug candidates have entered Phase I and two have completed Phase IIb clinical studies. Dr Mowbray gained both BSc and PhD degrees in chemistry from the University of Exeter and completed postdoctoral fellowships at the University of British Columbia and the University of Nottingham. Dr. Mowbray is a Fellow of the Royal Society of Chemistry and is an author of over 35 scientific publications and an inventor on 15 patents.

Dr. Paul Willis

Senior Director of Drug Discovery
Medicines for Malaria Venture

Dr. Paul Willis is a Medicinal Chemist and Senior Director of Drug Discovery at Medicines for Malaria Venture where he manages a portfolio of drug discovery projects, working with both pharmaceutical companies and academic partners to deliver antimalarial drug candidates. He also leads MMV's Open Science activities, including the Pathogen Box and Pandemic Response box projects, compound collections provided to screeners for free, in return for which scientist agree to release the results into the public domain. He is a member of the GHIT HTLP panel and the UK EPSRC Peer Review College. He was previously a team leader and project leader at AstraZeneca, working on cardiovascular, respiratory and anti-inflammatory drug discovery projects, which ultimately delivered two marketed drugs.

Session 2:
Discovery-stage technologies and innovations to address unmet medical needs

Dr. Atsuko Ochida

Associate Director
Drug Discovery Chemistry Laboratories
Neuroscience Drug Discovery Unit, Research
Takeda Pharmaceutical Company Limited

Dr. Atsuko Ochida is an associate director of Neuroscience Drug Discovery Unit at Takeda Pharmaceutical Company Limited. She obtained her Ph.D. in organic chemistry at Hokkaido University in 2006. After working at Stanford University as a postdoctoral fellow (B. M. Trost Lab), she joined Takeda in 2007 and she has gained experience and expertise in medicinal chemistry, chemical technology and leading projects. With 12 years of experience across various therapeutic areas including diabetes, obesity, inflammatory diseases and autoimmune disorders, she has been involved in overall drug discovery process including hit finding, lead generation/optimization and preclinical stage. Since 2017, she has been working on several drug discovery projects funded by GHIT through external partnerships. One of the programs she is involved in is Booster consortium being led by DND*i* aimed to generate lead molecules targeting Chagas disease and Leishmaniasis. She is also leading chemistry activities on hit-to-lead programs targeting generation of antimalarials and antituberculosis agents in collaboration with MMV and TB Alliance respectively.

Dr. Erica Pasini

Senior Scientist
Department of Parasitology
Biomedical Primate Research Centre (BPRC)

Dr. Erica Pasini is a senior scientist in the Department of Parasitology at the Biomedical Primate Research Centre (BPRC), Rijswijk. After her MSc in Pharmaceutical Chemistry and a Ph.D. in Malaria Drug Development from Milan University (Italy), Erica moved to the Liverpool School of Tropical Medicine to expand her knowledge on malaria and perfect her biochemistry skills. In 2004, she moved to her current position driven by a desire to contribute to the discovery/development of drugs and vaccines against malaria using non-human primate (NHP) models. At BPRC she became a leader in the application of 'omics technologies to the field of malaria. Aside of 'omics, Erica is interested in hematopoiesis and blood stage culture of malaria parasites (chiefly P. vivax), the modeling of cerebral malaria in NHPs and the understanding of malaria immunity.

Prof. Leann Tilley

Redmond Barry Distinguished Professor and
Georgina Sweet Australian Research Council
Australian Laureate Fellow
The University of Melbourne

Prof. Leann Tilley is Professor of Biochemistry and Molecular Biology at the Bio21 Institute, University of Melbourne. Leann was awarded a Georgina Sweet Australian Laureate Fellowship from the Australian Research Council to develop new therapies for malaria parasites. As part of the Laureate program, Leann's laboratory is implementing new imaging modalities, including cryo Electron Microscopy. Leann believes that the development of novel and effective antimalarial drugs will require innovative approaches involving Academic/ Private/ Public partnerships. Her lab is using 3D structural analysis of cells and molecules, correlative 'omics approaches, molecular genetics and modelling approaches to rationally design new antimalarials. Leann is working with colleagues from Takeda Pharmaceuticals and Medicines for Malaria Venture to discover new parasite-specific compounds that target proteastasis.

Dr. Yimin Wu

Scientific Advisor
PATH's Malaria Vaccine Initiative (MVI)

With over 25 years in malaria research and 15 years in malaria vaccine development, Dr. Yimin Wu serves as an scientific advisor in PATH's Malaria Vaccine Initiative (MVI), leading, coordinating, and facilitating multiple research and translational projects on malaria vaccine development. Prior to joining MVI, Yimin was the head of the Product Development Unit in the Malaria Vaccine Development Branch at the National Institute of Allergy and Infectious Diseases (NIAID), USA, from 2003 to 2015. She directed and managed the life cycle of the development of malaria vaccine candidates from manufacturer release to preclinical and clinical evaluations, including regulatory submissions of INDs and IMPDs. She also led formulation research to improve immunogenicity of malaria vaccine candidates, led research and development of field-based assays to evaluate vaccine efficacy in malaria-endemic regions, and led multi-site/multi-country testing of clinical specimens. Prior to NIAID she headed the Malaria Program at the American Type Culture Collection, where she conducted malaria research and served as the inaugural director of the Malaria Research and Reference Reagent Resource Center, known as MR4 by the malaria research community. She earned her BM at Shanghai University of Chinese Medicine and Ph.D at Southern Methodist University.

Session 3:
Development-stage technologies and innovations to address unmet medical needs

Prof. Toshihiro Horii

Head
Department of Malaria Vaccine Development

Prof. Toshihiro Horii, Head of the Department of Malaria Vaccine Development has worked on development of malaria vaccine particularly the serine repeat antigen 5 of P. falciparum since 1984. Aside from basic studies, he has been actively involved in epidemiological work in several countries (Burkina Faso and Uganda; Solomon Islands, Thailand), animal studies in monkeys and chimpanzee, GMP production, GLP studies, clinical trials and coordination with various regulatory authorities. He is the inventor for NPC-SE36 (formerly BK-SE36) and NPC-SE36/CpG. An awardee of the 2004 Koizumi Prize (from the Japanese Society of Parasitology) and 2014 Aikawa Masamichi Prize (from the Japanese Society of Tropical Medicine), he has continually served as external grant reviewer for The Ministry of Education, Science, Sports and Culture of Japan (MEXT); The ministry of Agriculture, Forestry and Fisheries (MAFF); and New Energy and Industrial Technology Development Organization (NEDO), Japan; as well as being a recipient of research grants from WHO/TDR, MEXT, AMED, NEDO and GHIT. He has authored/co-authored more than 190 peer reviewed articles/reviews.

Dr. Charles Mowbray

Discovery Director
DND*i*

Dr. Charles Mowbray is the Discovery Director at DND*i* responsible for advancing new chemical entities into development. He joined DND*i* in 2011 and has worked extensively on leishmaniasis and other kinetoplastid diseases. Dr. Mowbray also conceived the NTD Drug Discovery Booster consortium with 8 global pharmaceutical companies. He serves as an expert advisor to organisations working on medicinal chemistry, neglected diseases and global health projects. Dr. Mowbray joined Pfizer in Sandwich, UK in 1992 and spent 19 years working as a medicinal chemist and project leader across multiple diseases, target classes and medicinal chemistry strategies and from target selection through to clinical candidate delivery. Five of these drug candidates have entered Phase I and two have completed Phase IIb clinical studies. Dr Mowbray gained both BSc and PhD degrees in chemistry from the University of Exeter and completed postdoctoral fellowships at the University of British Columbia and the University of Nottingham. Dr. Mowbray is a Fellow of the Royal Society of Chemistry and is an author of over 35 scientific publications and an inventor on 15 patents.

Dr. Abhay Satoskar

Professor and Vice Chair for Research
Department of Pathology
The Ohio State University

Dr. Abhay Satoskar is a Professor and Vice Chair for Research in the Department of Pathology at The Ohio State University. Dr. Satoskar earned his MD from the Department of Pathology, King Edward VII Memorial Hospital, University of Bombay in Bombay, India and his PhD in the Department of Immunology, University of Strathclyde in Glasgow, UK. He completed his post-doctoral trainings at Max-Planck Institute for Immunobiology Germany and Harvard School of Public Health. Dr. Satoskar's research interests are immunology and neglected tropical infectious diseases such as leishmaniasis and Chagas disease to develop novel vaccines and treatments. A GHIT funded team of international experts led by him has developed a live attenuated vaccine for leishmaniasis. Dr. Satoskar has authored more than 220 publications and he serves on editorial boards of several journals. He served on panels of national and international funding agencies including NIH, NRF (South Africa), and NSERC (Canada). He is also a Visiting Professor at Nagasaki University Institute of Tropical Medicine.

Lunch Session: Proposal Writing Seminar

Dr. Ann Mills-Duggan

Partner, Innovations Division
Wellcome

Dr. Ann Mills-Duggan joined the Wellcome Trust in 2010 and currently heads the Innovator Award Fund which supports discovery and development programs worldwide. Prior to joining Wellcome she spent over twenty years in the pharmaceutical industry, most recently with UCB and previously with GlaxoSmithKline and GlaxoWellcome, working in research, licensing, alliance management and life science investing. A biochemist by training Ann is a graduate of the University of Bath and earned her PhD at Imperial College, London. In addition Dr. Mills-Duggan is a member of the Selection Committees for the Global Health Innovative Technology Fund (Japan) and the Research Investment for Global Health Technology Fund (South Korea), is on several UK strategy panels including the Steering Board of the UK's HealthTech and Medicines Knowledge Transfer Network and is a Board Director of Acesion Pharma (Denmark).

Session 4:

Partnership matters! Coincidence or destiny? How and where can we meet the right partners?

Dr. Tomoko Ishino

Associate Professor
Division of Molecular Parasitology
Proteo-Science Center (PROS), Ehime University

Dr. Tomoko Ishino is an associate Professor in Division of Molecular Parasitology, PROS, Ehime University. She earned her Ph.D. in Pharmaceutical Science (developmental biology) at the University of Tokyo in 2001. She started working on malaria parasites as a postdoctoral fellow in Mie University to elucidate the molecular mechanisms of sporozoite infection of mammalian hosts. She identified totally 7 novel secretory proteins required for sporozoite migration towards hepatocytes, recognition of hepatocytes, or development inside hepatocytes by the reverse-genetics. After working at Institut Pasteur (Dr. Menard lab) for 3 years as a postdoctoral fellow, especially on the liver stage parasite biology, she joined Ehime University in 2009. Her major research interests are: (1) elucidation of molecular mechanisms of sporozoite invasion of target cells; (2) elucidation of molecular mechanisms of sexual-stage development; (3) screening for novel candidates as transmission-blocking vaccine targets. Aside from the research, she was also serving as a senior scientific research specialist, Ministry of Education, Culture, Sports, Science and Technology, from 2011 to 2013.

Dr. Yimin Wu

Scientific Advisor
PATH's Malaria Vaccine Initiative (MVI)

With over 25 years in malaria research and 15 years in malaria vaccine development, Dr. Yimin Wu serves as an scientific advisor in PATH's Malaria Vaccine Initiative (MVI), leading, coordinating, and facilitating multiple research and translational projects on malaria vaccine development. Prior to joining MVI, Yimin was the head of the Product Development Unit in the Malaria Vaccine Development Branch at the National Institute of Allergy and Infectious Diseases (NIAID), USA, from 2003 to 2015. She directed and managed the life cycle of the development of malaria vaccine candidates from manufacturer release to preclinical and clinical evaluations, including regulatory submissions of INDs and IMPDs. She also led formulation research to improve immunogenicity of malaria vaccine candidates, led research and development of field-based assays to evaluate vaccine efficacy in malaria-endemic regions, and led multi-site/multi-country testing of clinical specimens. Prior to NIAID she headed the Malaria Program at the American Type Culture Collection, where she conducted malaria research and served as the inaugural director of the Malaria Research and Reference Reagent Resource Center, known as MR4 by the malaria research community. She earned her BM at Shanghai University of Chinese Medicine and Ph.D at Southern Methodist University.

Prof. Tomoyoshi Nozaki

Professor
Graduate School of Medicine
The University of Tokyo

Prof. Tomoyoshi Nozaki, M.D., Ph.D. graduated from Keio University School of Medicine in 1987. He spent seven years of post-doctoral training on Molecular Parasitology at NIH and the Rockefeller University. During his post-doctoral training, he worked on genome plasticity, drug resistance, and virulence mechanisms of Trypanosoma cruzi, causing Chagas' disease and T. brucei, causing African sleeping sickness. When he moved back to Japan in 1996, he started investigation on the virulence mechanisms of Entamoeba histolytica, causing amebiasis, and its unique sulfur-containing amino acid metabolisms, at Keio University. In 1999, he moved to National Institute of Infectious Diseases as a laboratory head, and in 2004, to Gunma University as Full Professor. In 2008, he returned to National Institute of Infectious Diseases as Director of Department of Parasitology. He was also appointed as Professor of University of Tsukuba and Waseda University. In 2017, he was appointed as Professor of Graduate School of Medicine, The University of Tokyo. He is also currently serving as President of Japanese Society of Parasitology. Last 25 years he has been mainly investigating two aspects of amebiasis. He has been working on the virulence mechanisms, mainly focusing on vesicular trafficking, trogocytosis, phagocytosis, and secretion of cytolytic factors. He has also been vigorously working on drug development against amebiasis and malaria targeting essential metabolisms such as sulfur-containing amino acids and coenzyme A biosynthesis and degradation. He is also working on the unique evolution of the mitochondrion-related organelles in anaerobic protists with the prospect of drug development.

Dr. Paul Willis

Senior Director of Drug Discovery
Medicines for Malaria Venture

Dr. Paul Willis is a Medicinal Chemist and Senior Director of Drug Discovery at Medicines for Malaria Venture where he manages a portfolio of drug discovery projects, working with both pharmaceutical companies and academic partners to deliver antimalarial drug candidates. He also leads MMV's Open Science activities, including the Pathogen Box and Pandemic Response box projects, compound collections provided to screeners for free, in return for which scientist agree to release the results into the public domain. He is a member of the GHIT HTLP panel and the UK EPSRC Peer Review College. He was previously a team leader and project leader at AstraZeneca, working on cardiovascular, respiratory and anti-inflammatory drug discovery projects, which ultimately delivered two marketed drugs.

Session 5:

Partnership matters!-Unlocking the secret of successful partnerships for late-stage projects

Mr. Fumiya Domoto

Planning and Management
Healthcare Policy and CSR
Astellas Pharma Inc.

Mr. Fumiya Domoto joined Astellas Pharma Inc. in 2010. He worked on clinical development departments for more than six years and worked for various projects, which include leading global first-in-human oncology study as the clinical program manager. In addition, he worked for global task force to install risk based monitoring and established SOPs and tools to implement it in Astellas. In 2016, he joined Healthcare Policy and CSR department, and has led access to health activities within Astellas and launched multiple access to health initiatives in low and middle income countries as cross-department activities. In his current department, he is in charge of both CSR and Healthcare Policy works as well. He has led CSR activities at corporate level, including update of CSR materiality matrix, creation of integrated corporate report and managed corporate CSR committee as its secretariat. Also, He worked for trade association initiatives at Japan Pharmaceutical Manufacturers Association (JPMA) and International Federation of Pharmaceutical Manufacturers & Associations, and as JPMA project, he launched a JPMA new flagship initiative to improve proper use of medicines in collaboration with Japanese national hospital and national hospital in Vietnams. He earned a Master of Engineering degree from synthetic chemistry and biological chemistry, Kyoto University in 2010.

Ms. Ryo Kobayashi

Application Specialist
In Vitro Diagnostics, Medical Systems Business Division
FUJIFILM Corporation

Ms. Ryo Kobayashi is Application Specialist of In Vitro Diagnostics Division, Medical Systems Business Division at FUJIFILM Corporation. In her role, she is engaged with global health related projects with a particular focus on the product launch of Fujifilm SILVAMP TB LAM assay in close collaboration with FIND and GHIT. Prior to the current role, she worked as Local Networks Manager at the United Nations Global Compact, the platform used to advance corporate sustainability in more than 160 countries. There, she led to help companies in the Asian region to understand what responsible business means within a local context and worked to promote the uptake of CSR at the grassroots level. She holds a MPH from the School of Tropical Medicine and Global Health, Nagasaki University.

Dr. Remco de Vrueh

Senior Program Manager
Lygature

Dr. Remco de Vrueh joined Lygature as Senior Program Manager in 2013 and co-leads the Neglected Tropical Diseases project portfolio. Currently, he coordinates the Pediatric Praziquantel Consortium and the DTECT-Schisto partnership. Since he obtained his PhD in drug delivery in 1999, he fulfilled project management positions within the pharmaceutical industry, health research funding agencies and the Dutch Medicines Evaluation Board. He has also worked as senior consultant for a communication consultancy & PA consultancy firm with a strong focus on corporate social responsibility and sustainability. This diverse background helps him to initiate new public-private partnerships and to keep these on course during implementation. He enjoys his role as partnership broker and consolidating sometimes different perspectives into one vision. Throughout his career Dr De Vrueh has valued sharing his knowledge through teaching at various Universities, mentoring colleagues as well as Master students, providing numerous presentations at meetings and co-authoring more than 30 scientific papers and book chapters.

Dr. Emmanuel Moreau

Senior Scientific Officer, IVD Technology Development
Foundation for Innovative New Diagnostics

Dr. Emmanuel Moreau joined FIND in February 2018 as Senior Scientific Officer – Technology Development. He is in charge of managing R&D initiatives in the Tuberculosis program and acting as project manager for the Fujifilm – FIND co-development of the Silvamp TB LAM assay. Dr. Moreau has extensive experience in all aspects of the IVD product life cycle, having spent a decade working for major clinical diagnostics companies such as bioMérieux (France) and Philips Minicare Diagnostics (The Netherlands). He led the development of several IVD-grade immunoassays for central laboratory platforms and point-of-care devices for patient bedside testing. Dr. Moreau's expertise includes assay feasibility, design & development, transfer to manufacturing & validation, as well as support to clinical trials, regulatory compliance and market access. Dr. Moreau holds a PhD in Immunology from Université Paris 5 – René Descartes (France) and a RAPS certification for Regulatory Affairs.

Session 6:

Funders' role and strategy in catalyzing innovations for neglected patients

Dr. Ann Mills-Duggan

Partner, Innovations Division
Wellcome

Dr. Ann Mills-Duggan joined the Wellcome Trust in 2010 and currently heads the Innovator Award Fund which supports discovery and development programs worldwide. Prior to joining Wellcome she spent over twenty years in the pharmaceutical industry, most recently with UCB and previously with GlaxoSmithKline and GlaxoWellcome, working in research, licensing, alliance management and life science investing. A biochemist by training Ann is a graduate of the University of Bath and earned her PhD at Imperial College, London. In addition Dr. Mills-Duggan is a member of the Selection Committees for the Global Health Innovative Technology Fund (Japan) and the Research Investment for Global Health Technology Fund (South Korea), is on several UK strategy panels including the Steering Board of the UK's HealthTech and Medicines Knowledge Transfer Network and is a Board Director of Acesion Pharma (Denmark).

Ms. Lara Pandya

Strategic Partnerships Officer
European & Developing Countries Clinical Trials Partnership (EDCTP)

Ms. Lara Pandya graduated from the University of Bristol, where she completed both her bachelors and Master of Science in Geography. She subsequently obtained a Master's in Public Health with the London School of Hygiene & Tropical Medicine (LSHTM). She has prior experience in hospital administration and international clinical trial management, in addition to having worked in resource development at the International AIDS Vaccine Initiative (IAVI) and in the project management of European Union-funded grants at the Amsterdam Institute for Global Health and Development (AIGHD). Lara is a Strategic Partnerships Officer at the European & Developing Countries Clinical Trials Partnership (EDCTP), having formerly been an EDCTP Project Officer from 2007 to 2010. She is responsible for building and managing partnerships with key public and private stakeholders, particularly in the areas of HIV and neglected infectious diseases, and for facilitating the coordination of European national research programmes on infectious diseases. She has a personal interest in research uptake into policy and ensuring access to health innovations in low- and middle-income countries.

Mr. Masahiko Noda

Managing Director
Department of International Affairs
Japan Agency for Medical Research and Development (AMED)

Mr. Masahiko NODA is the Managing Director of the Department of International Affairs at the Japan Agency for Medical Research and Development (AMED), which was established on April 1st 2015. He previously joined the p reparatory office for launching AMED in 2014. Mr. NODA graduated from Shinshu University, Graduate School of Science (M.Sc.). He joined the Research Development Corporation of Japan (JRDC) in 1982. He served as an official at the International Affairs Division of the Science and Technology Agency (STA) for two years from 1988. In 1990, he joined the Japan Science and Technology Agency (JST). He participated in the planning and launching of the National Museum of Emerging Science and Innovation (Miraikan), as well as the Center for Research and Development Strategy (CRDS) and the Center for Low Carbon Society Strategy (LCS). He also served as special staff at the Council for Science and Technology in 2000 and for the Millennium project of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in 2001. In 2012, he joined the School of Engineering at the University of Tokyo in order to support their research management.

Follow us!

@GHITFund Global Health Innovative Technology (GHIT) Fund

Use Hashtag: #RDForum #GHITFund

Exhibitor

Time : 12:00 - 18:00
Venue : Seminar Room CD

The Japan Agency for Medical Research and Development, AMED, is a national funding agency that promotes leading-edge medical innovation from discovery and development to clinical application. AMED aims to achieve the world's healthiest and longest-living people by creating the world's most advanced medical technologies and services, and also aims to become a pillar of Japan's economy by fostering medicine, drugs, and medical devices as strategic industries.

https://www.amed.go.jp/

A not-for-profit research and development organization, DND*i* works to deliver new treatments for neglected diseases, including leishmaniasis, filarial infections, sleeping sickness, Chagas disease, and mycetoma, and for neglected patients, including children with HIV and people living with hepatitis C virus. DND*i* has delivered eight new treatments to date, including new drug combinations for visceral leishmaniasis, two fixed-dose antimalarials, and DND*i*'s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.

DND*i* website: www.dndi.org / DND*i* Japan website: www.dndijapan.org

---

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai's corporate philosophy is to give first thought to patients and their families, and to increase the benefits that health care provides to them. Under this philosophy, the company endeavors to become a human health care (hhc) company. In line with its hhc philosophy, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

https://www.eisai.co.jp/

Japan Alliance on Global NTDs (JAGntd) is an alliance consisting of organizations and individuals working towards the global effort of eradication, elimination, and control of NTDs, and promotes Japan's contribution to global NTD work. Our vision is to contribute to the global targets of NTDs as established stated by the WHO. JAGntd will promote the visibility and effectiveness of Japan's contribution to the global NTD programs.

https://jagntd.org/

At the Center for Integrative Medical Sciences, we aim to elucidate the pathogenesis of human diseases and establish new therapeutic methodologies by conducting cutting-edge research on human genome and immune function. To that end, we have established four Divisions: (1) Division of Genomic Medicine, (2) Division of Human Immunology, (3) Division of Disease Systems Biology, and (4) Division of Next Generation Cancer Immunology. These groups work together to promote state-of-the-art research. We apply multiomics analyses across each hierarchy of genome, proteins, lipids, cells, tissues, and individuals by utilizing computational methods of data analysis, combining statistics and mathematics. We also establish a platform that will allow us to comprehend the results obtained in experimental animals and apply them to human immunology research, and to elucidate mechanisms of human pathology using experimental systems such as cells and animal models. Further, we utilize these infrastructures to develop next generation cancer immunology research.

https://www.ims.riken.jp/english/

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.

https://www.takeda.com/

The Access and Delivery Partnership (ADP) supports low-and middle-income countries to strengthen and harmonize policies and systems, and build the capacities of key people and institutions to drive the necessary reforms – paving the way for sustainable, country-led progress toward universal health coverage. ADP leverages the unique areas of expertise of its core partners – the United Nations Development Programme (UNDP), the World Health Organization (WHO), the Special Programme for Research and Training in Tropical Diseases (TDR) and PATH – to bring together stakeholders across sectors and develop cross-cutting solutions to improve health care delivery.

http://www.adphealth.org/

Memo

Memo

Memo

Memo